Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome

Rami S. Komrokji, Jeffrey E. Lancet, Arlene S. Swern, Nianhang Chen, Jennifer Paleveda, Richard Lush, Hussain I. Saba, Alan F. List

Blood (2012) 120 (17): 3419–3424.

https://doi.org/10.1182/blood-2012-03-415661

Published: 2012

Journal Articles

Phase I/II Trial of High-Dose Melphalan (M) and Topotecan (T) Followed by Autologous Stem Cell Rescue in Patients ≤ 60 and > 60 Years of Age with Multiple Myeloma (MM).

Daniel Sullivan, MD, Melissa Alsina, MD, Claudio Anasetti, MD, Teresa Field, MD, PhD, Mohamed Kharfan-Dabaja, MD, Hugo Fernandez, MD, William Dalton, PhD, MD, Ernesto Ayala, MD, Jyoti Raychaudhuri, MD, Lia Perez, MD, Janelle Perkins, PharmD, Michael Schell, PhD, Christine McIsaac, RN, Beth Maddox, RN, Jana Gump, BS, Richard Lush, PhD, Tony Frudakis, PhD

Blood (2007) 110 (11): 943.

https://doi.org/10.1182/blood.V110.11.943.943

Published: 2007

Journal Articles

Two-Stage Pharmacokinetic & Efficacy Study of Lenalidomide Alone or Combined with Recombinant Erythropoietin (EPO) in Lower Risk MDS EPO-Failures [PK-002].

Alan F. List, MD, Jeffrey E. Lancet, MD, Magda Melchert, MD, Hussein Saba, MD, Richard Lush, PhD, Jian Yu, PhD, Nianhang Chen, PhD, Michele Schmidt, RN, Robert Knight, MD

Blood (2007) 110 (11): 4626.

https://doi.org/10.1182/blood.V110.11.4626.4626

Published: 2007

Journal Articles

A Pharmacokinetic & Pharmacodynamic Study of Oral Lenalidomide in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes.

Anfan Wu, PhD, Alan List, MD, Richard Lush, MD, Kelly Bretz, BS, Robert Knight, MD, Jerry Zeldis, MD, Henry Lau, PhD

Blood (2006) 108 (11): 4854.

https://doi.org/10.1182/blood.V108.11.4854.4854

Published: 2006

Journal Articles

Ifosphamide, Etoposide and Epirubicin (IVE) Is an Effective Combined Salvage and Peripheral Blood Stem Cell Mobilisation Regimen for Transplant-Eligible Patients with Lymphoma.

Mark J. Bishton, Richard Lush, Nigel H. Russell, Bronwen E. Shaw, Andrew P. Haynes

Blood (2006) 108 (11): 2432.

https://doi.org/10.1182/blood.V108.11.2432.2432

Published: 2006

Journal Articles

The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation

Blood (2002) 100 (9): 3108–3114.

https://doi.org/10.1182/blood-2002-02-0506

Published: 2002

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome

Phase I/II Trial of High-Dose Melphalan (M) and Topotecan (T) Followed by Autologous Stem Cell Rescue in Patients ≤ 60 and > 60 Years of Age with Multiple Myeloma (MM).

Two-Stage Pharmacokinetic & Efficacy Study of Lenalidomide Alone or Combined with Recombinant Erythropoietin (EPO) in Lower Risk MDS EPO-Failures [PK-002].

A Pharmacokinetic & Pharmacodynamic Study of Oral Lenalidomide in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes.

Ifosphamide, Etoposide and Epirubicin (IVE) Is an Effective Combined Salvage and Peripheral Blood Stem Cell Mobilisation Regimen for Transplant-Eligible Patients with Lymphoma.

The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation

Email alerts

ASH Publications

American Society of Hematology

Update search

Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome

Phase I/II Trial of High-Dose Melphalan (M) and Topotecan (T) Followed by Autologous Stem Cell Rescue in Patients ≤ 60 and > 60 Years of Age with Multiple Myeloma (MM).

Two-Stage Pharmacokinetic & Efficacy Study of Lenalidomide Alone or Combined with Recombinant Erythropoietin (EPO) in Lower Risk MDS EPO-Failures [PK-002].

A Pharmacokinetic & Pharmacodynamic Study of Oral Lenalidomide in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes.

Ifosphamide, Etoposide and Epirubicin (IVE) Is an Effective Combined Salvage and Peripheral Blood Stem Cell Mobilisation Regimen for Transplant-Eligible Patients with Lymphoma.

The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only